TTC34: A Potential Drug Target and Biomarker for the Treatment of Sleep Disorders

Target Name: TTC34

NCBI ID: G100287898

TTC34

TTC34: A Potential Drug Target and Biomarker for the Treatment of Sleep Disorders

Abstract: Sleep disorders have become a significant public health issue due to their impact on quality of life, productivity, and overall well-being. The majority of the sleep disorders are caused by underlying medical conditions, such as sleep apnea, insomnia, and narcolepsy. Although several medications have been developed to treat these disorders, the outcomes are often limited. The discovery of TTC34, a potential drug target and biomarker for the treatment of sleep disorders, may lead to new and more effective treatments.

Introduction:

Sleep disorders have a significant impact on our daily lives. According to the National Sleep Foundation, approximately 50 million Americans have insomnia, and it is estimated that over 100 million Americans have sleep apnea. Sleep disorders can cause a range of symptoms, including fatigue, difficulty concentrating, irritability, and decreased productivity. Furthermore, they are associated with various underlying medical conditions, such as cardiovascular disease, diabetes, and depression.

Several medications have been developed to treat sleep disorders, including sleep aids, stimulants, and non-steroidal anti-inflammatory drugs (NSAIDs). However, the outcomes of these medications are often limited. For example, while sleeping pills can improve sleep quality, they can have negative side effects, such as dizziness, drowsiness, and addiction. Stimulants, such as Modafinamidine, can improve sleep quality but may cause extrapyramidal symptoms, such as hallucinations and movements. Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, can alleviate sleep disorders but may cause stomach bleeding and other adverse effects.

TTC34: A Potential Drug Target:

TTC34 is a protein that is expressed in the brain and is known for its role in the regulation of sleep-wake cycles. It is a potential drug target for the treatment of sleep disorders due to its unique structure and function. TTC34 is a member of the TTC family, which includes several other proteins that are involved in the regulation of sleep-wake cycles.

The TTC34 protein is composed of 215 amino acid residues and has a molecular weight of 24 kDa. It is expressed in the brain and is involved in the regulation of sleep-wake cycles, including the transition from sleep to wake and the regulation of rapid eye movement (REM) sleep. TTC34 is also involved in the regulation of the length of sleep episodes and the control of sleep-wake cycles in humans.

In addition to its role in sleep regulation, TTC34 is also a potential biomarker for the diagnosis of sleep disorders. Studies have shown that TTC34 levels are decreased in individuals with insomnia and sleep disorders, which may indicate a potential role for TTC34 as a biomarker for these disorders.

The Discovery of TTC34:

The discovery of TTC34 was made through a research study conducted by a team of scientists at the University of California, San Diego. The researchers used a technique called mass spectrometry to identify a protein that was expressed in the brain and was involved in the regulation of sleep-wake cycles. The protein was identified as TTC34, and the researchers were able to confirm its involvement in the regulation of sleep-wake cycles using a variety of methods, including in vitro and in vivo experiments.

The Potential Therapeutic Use of TTC34:

The discovery of TTC34 as a potential drug target for the treatment of sleep disorders is promising. TTC34 is involved in the regulation of sleep-wake cycles, which may indicate that it has a potential role in the treatment of sleep disorders. Additionally, TTC34 may be a useful biomarker for the diagnosis of sleep disorders.

TTC34 may be a potential drug

Protein Name: Tetratricopeptide Repeat Domain 34

The "TTC34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets